Put two ophthalmology practices side by side, both collecting $1.5 million a year, and from the outside they look like the same business. Same specialty, revenue, and general category of patients walking through the door. But the way those two practices make money, the risks they carry, margins they produce, and what they're actually worth to a buyer have almost nothing in common.
Ophthalmology is at least two businesses operating under one specialty name. The front of the eye and the back of the eye are different economic worlds, and anyone evaluating an ophthalmology practice who doesn't understand the distinction is going to get the numbers wrong.
Anterior Segment Economics
Anterior segment ophthalmology covers the cornea, the lens, and the surrounding anatomy. The procedures that drive revenue here are refractive surgery (LASIK, PRK, SMILE, ICL), premium cataract surgery with advanced lens implants, and corneal treatments. These are procedures patients choose to have. Insurance doesn't cover LASIK because it isn't medically necessary, which means the patient pays out of pocket, typically $3,000 to $7,000 per eye depending on the procedure and the market. There are no insurance claims to file, reimbursement rates to negotiate, and prior authorizations to obtain. The patient pays and the practice collects, usually at the time of service.
The margins are significant and a single refractive procedure can generate thousands of dollars against a relatively fixed cost base, and when the practice is running at volume, each additional procedure adds revenue without proportionally adding cost.
The revenue carries a dependency that most people outside the specialty don't fully appreciate. It's almost entirely driven by marketing. Patients don't get referred to a refractive surgeon because they have a disease. They find the practice through Google searches, social media, reviews, and paid advertising. A refractive practice without an active marketing operation is a refractive practice with an empty surgical schedule, and that reality shows up fast when the physician decides to wind down and stops investing in patient acquisition.
Premium cataract surgery sits in a slightly different position. The base cataract procedure is medically necessary and covered by Medicare, but the premium lens upgrade is an out of pocket cost the patient elects. This creates a hybrid revenue model with strong margins on the upgrade, but the practice needs a patient education process that communicates the value without pressuring the patient.
Posterior Segment Economics
Posterior segment ophthalmology covers the retina, vitreous, optic nerve, and structures behind the lens. The conditions treated here aren't elective. Macular degeneration, diabetic retinopathy, retinal detachments, and glaucoma are medical emergencies and chronic diseases that cause blindness if left untreated.
The business model is fundamentally different because the revenue is almost entirely insurance based. Medicare and Medicaid cover the majority of retinal care, and cash pay is minimal because patients aren't choosing to have retinal injections the way they choose to have LASIK. They need them or they lose their vision.
The margins are tighter. Revenue per procedure is lower, billing is more complex, compliance overhead is higher, and the practice is exposed to reimbursement rate changes that a cash pay practice doesn't face. A retina practice collecting $1.5 million this year might collect $1.4 million next year on identical volume simply because CMS reduced a reimbursement rate.
But the retina practice has something the refractive practice doesn't: structural patient volume that doesn't depend on marketing. A patient diagnosed with macular degeneration needs injections every 4 to 8 weeks for years. Glaucoma patients come back for the rest of their lives. The patient base compounds over time rather than turning over, and when a recession hits, elective refractive procedures drop while retinal disease doesn't respond to the economy.
Referral networks work differently too. A retina practice builds volume through referrals from optometrists and general ophthalmologists who send their complex cases to the specialist. Those relationships are built over years of trust and clinical quality, which makes them harder to build and to lose.
Same Number, Different Valuation
The same $1.5 million in revenue produces a very different valuation depending on which side of the eye it comes from.
The refractive practice likely has higher margins, stronger per procedure economics, and more upside if the buyer can maintain the marketing engine. But the revenue is fragile because it depends on continuous patient acquisition, and if the marketing stops, revenue can decline rapidly.
The retina practice likely has lower margins but more predictable and recurring revenue driven by chronic disease management and established referral networks. The revenue is less sensitive to marketing, economic cycles, and more likely to survive an ownership transition intact.
Neither model is better. They carry different risk profiles, growth levers, and operational requirements. A buyer who understands both is in a stronger position than one who treats all ophthalmology revenue as interchangeable.
Different Transitions for Different Practices
The coming wave of ophthalmology retirements doesn't distinguish between anterior and posterior. Solo practitioners in both subspecialties are aging out, but the transition dynamics are different for each.
A refractive practice that loses its founding surgeon and its marketing momentum simultaneously can lose value fast. The transition has to preserve both clinical capability and the marketing infrastructure that keeps patients flowing through the door.
A retina practice that loses its founding surgeon faces a different challenge: maintaining the referral relationships that took decades to build. If the referring optometrists don't trust the successor, those referral patterns shift to a competitor, and rebuilding them takes years.
In both cases, the practices that transition successfully are the ones where succession is planned in advance, the right successor is integrated before the founder leaves, and the operational infrastructure is strong enough to survive the change in leadership. Understanding which kind of practice you're looking at is the starting point for every intelligent conversation about ophthalmology acquisition, because the number on the top line is just the beginning.
This article is for general educational purposes and is not legal or financial advice.
Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you are evaluating the ophthalmology market and want to understand how different practice models affect transition planning, we are open to thoughtful conversations.
Contact info@verdira.com | 307-381-3734 | verdira.com
